Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010 (2010), Article ID 698730, 11 pages
Review Article

PPARs in the Renal Regulation of Systemic Blood Pressure

Department of Regenerative Cardiology, Spanish National Cardiovascular Research Center (CNIC), 28029 Madrid, Spain

Received 23 September 2009; Revised 24 February 2010; Accepted 31 March 2010

Academic Editor: Tianxin Yang

Copyright © 2010 Tamás Rőszer and Mercedes Ricote. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Recent research has revealed roles for the peroxisome proliferator activated receptor (PPAR) family of transcription factors in blood pressure regulation, expanding the possible therapeutic use of PPAR ligands. PPAR and PPAR modulate the renin-angiotensin-aldosterone system (RAAS), a major regulator of systemic blood pressure and interstitial fluid volume by transcriptional control of renin, angiotensinogen, angiotensin converting enzyme (ACE) and angiotensin II receptor 1 (AT-R1). Blockade of RAAS is an important therapeutic target in hypertension management and attenuates microvascular damage, glomerular inflammation and left ventricular hypertrophy in hypertensive patients and also show antidiabetic effects. The mechanisms underlying the benefits of RAAS inhibition appear to involve PPAR -regulated pathways. This review summarizes current knowledge on the role of PPARs in the transcriptional control of the RAAS and the possible use of PPAR ligands in the treatment of RAAS dependent hypertension.